Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 17;75(5):1242–1249. doi: 10.1093/jac/dkaa016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 2. — (a) Participant serum estradiol concentration before (day 0) and during steady-state tenofovir/emtricitabine 300/200 mg (day 14), n = 15. Wilcoxon signed-rank paired comparison: P < 0.001. Vertical lines represent median (IQR) concentrations on day 0 and day 14. (b) Participant serum total testosterone concentration before (day 0) and during steady-state tenofovir and emtricitabine concentrations on day 14 post administration of tenofovir disoproxil fumarate/emtricitabine (300/200 mg), n = 15. Wilcoxon signed-rank paired comparison: P = 0.38. Vertical lines represent median (IQR) concentrations on day 0 and day 14. (c) Serum free testosterone concentration on day 0 and day 14; Wilcoxon signed-rank paired comparison: P = 0.68. Vertical lines represent median (IQR) concentrations on day 0 and day 14.